SubsidieMeestersMulti-omic data driven drug discovery and indication prioritisation platform in oncology
mCUBE is an AI-driven platform aimed at enhancing precision oncology by harmonizing clinical data and multi-omic analysis to identify new drug candidates for licensing to pharma companies.
Projectdetails
Introduction
With 20% of patients responding to their treatment and 10M dying every year, cancer is a recognized societal challenge. While data-driven approaches can double the clinical trials success rate, the pharma industry lacks tools to leverage the large amount of data generated in their drug discovery processes.
Project Overview
We are developing mCUBE, an AI-powered platform that scales precision oncology for drug discovery and repurposing.
Platform Features
Best-in-class and user-centric, mCUBE encapsulates:
- A cancer-agnostic clinical data harmonization module
- An integrative approach to multi-omic data analysis
Business Model Transition
As our solution increases in value and allows us to move up the value chain, our initial SaaS business model will progressively switch to a drug discovery model.
Goals
With mCUBE, we will:
- Identify and validate new drug candidates
- License IP assets to pharma companies
Future Expectations
By 2025, we expect to sign a deal of 25M with a biopharma partner. We will disrupt the oncology market for the benefit of cancer patients.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.495.788 |
| Totale projectbegroting | € 3.565.412 |
Tijdlijn
| Startdatum | 1-8-2022 |
| Einddatum | 31-7-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- EPIGENE LABS SASpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug developmentCherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing. | EIC Accelerator | € 2.499.831 | 2024 | Details |
The first IVDR-approved commercial software solutions for AI-powered RNA-based companion and precision cancer diagnostics of acute myeloid leukaemia and bladder cancerQlucore aims to revolutionize precision oncology by developing AI-driven diagnostic software for cancer, enhancing accuracy in gene analysis and improving survival rates across Europe. | EIC Accelerator | € 2.491.650 | 2024 | Details |
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors. | EIC Accelerator | € 2.496.112 | 2024 | Details |
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineeringThe project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer. | EIC Accelerator | € 2.434.790 | 2025 | Details |
FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPYMYCureX aims to evaluate the safety and efficacy of OMO-103, a novel MYC inhibitor, in combination with standard care for PDAC, while refining companion diagnostics for improved patient outcomes. | EIC Accelerator | € 2.494.504 | 2023 | Details |
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development
Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.
The first IVDR-approved commercial software solutions for AI-powered RNA-based companion and precision cancer diagnostics of acute myeloid leukaemia and bladder cancer
Qlucore aims to revolutionize precision oncology by developing AI-driven diagnostic software for cancer, enhancing accuracy in gene analysis and improving survival rates across Europe.
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.
The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors.
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering
The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.
FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPY
MYCureX aims to evaluate the safety and efficacy of OMO-103, a novel MYC inhibitor, in combination with standard care for PDAC, while refining companion diagnostics for improved patient outcomes.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Development of a high-throughput microplate based device to analyse the patient derived tumour microenvironment3DTUMOUR aims to enhance drug development success by providing patient-specific 3D bioprinted tumour models for ex vivo testing, improving treatment efficacy and reducing toxicity in cancer therapy. | ERC Proof of... | € 150.000 | 2024 | Details |
Nano-assisted digitalizing of cancer phenotyping for immunotherapyThe ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes. | ERC Consolid... | € 1.993.875 | 2023 | Details |
PIONEER-AI: Pushing Immune Optimization through Novel Engineering and Enhanced ResourcingDigi.Bio en Bubl ontwikkelen het PIONEER-AI platform om CAR-T celtherapieën sneller en goedkoper te evalueren, waardoor de behandeling van kankerpatiënten verbetert. | Mkb-innovati... | € 192.835 | 2023 | Details |
Preclinical validation and market analysis of a microMESH implant for brain cancer eradicationThe project aims to develop and validate a novel drug delivery implant, microMESH, for targeted chemo-immunotherapy in glioblastoma, enhancing treatment efficacy and patient outcomes. | ERC Proof of... | € 150.000 | 2022 | Details |
Foundation models for molecular diagnostics - machine learning with biological ‘common sense’FoundationDX aims to enhance molecular diagnostics by using self-supervised learning on diverse biomolecular data to accurately predict cancer subtypes and treatment outcomes without extensive labeled datasets. | ERC Consolid... | € 2.000.000 | 2024 | Details |
Development of a high-throughput microplate based device to analyse the patient derived tumour microenvironment
3DTUMOUR aims to enhance drug development success by providing patient-specific 3D bioprinted tumour models for ex vivo testing, improving treatment efficacy and reducing toxicity in cancer therapy.
Nano-assisted digitalizing of cancer phenotyping for immunotherapy
The ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes.
PIONEER-AI: Pushing Immune Optimization through Novel Engineering and Enhanced Resourcing
Digi.Bio en Bubl ontwikkelen het PIONEER-AI platform om CAR-T celtherapieën sneller en goedkoper te evalueren, waardoor de behandeling van kankerpatiënten verbetert.
Preclinical validation and market analysis of a microMESH implant for brain cancer eradication
The project aims to develop and validate a novel drug delivery implant, microMESH, for targeted chemo-immunotherapy in glioblastoma, enhancing treatment efficacy and patient outcomes.
Foundation models for molecular diagnostics - machine learning with biological ‘common sense’
FoundationDX aims to enhance molecular diagnostics by using self-supervised learning on diverse biomolecular data to accurately predict cancer subtypes and treatment outcomes without extensive labeled datasets.